Related Experiment Video
Updated: Jan 7, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behet disease
F Giansanti1, M L Barbera, L Virgili
1Eye Clinic, Department of Oto-Neuro-Ophthalmological Surgical Sciences, University of Firenze, Firen.
Purpose:
To report a case of posterior uveitis with retinal neovascularization in a patient with Behet disease treated with infliximab.
Methods:
A 50-year-old man with a history of recurrent relapses of ocular inflammation despite immunosuppressive therapy developed retinal neovascularization near the optic disk. The patient was treated with infliximab and followed up for 12 months.
Results:
Retinal neovascularization regressed 8 months after the first antitumor necrosis factor (TNF) treatment and with six infusions of infliximab. The ocular inflammation resolved almost completely.
Conclusions:
The result suggests that anti-TNF therapy may be effective in the treatment of retinal neovascularization caused by panuveitis in Behet disease. (Eur J Ophthalmol 2004; 14: #-8).
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Angle Closure Glaucoma: Treatment
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

